JP2015527316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015527316A5 JP2015527316A5 JP2015521033A JP2015521033A JP2015527316A5 JP 2015527316 A5 JP2015527316 A5 JP 2015527316A5 JP 2015521033 A JP2015521033 A JP 2015521033A JP 2015521033 A JP2015521033 A JP 2015521033A JP 2015527316 A5 JP2015527316 A5 JP 2015527316A5
- Authority
- JP
- Japan
- Prior art keywords
- hdac4
- group
- combination
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 9
- 102100021454 Histone deacetylase 4 Human genes 0.000 claims 10
- 101000899259 Homo sapiens Histone deacetylase 4 Proteins 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 230000030279 gene silencing Effects 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 230000003463 hyperproliferative effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 208000030224 brain astrocytoma Diseases 0.000 claims 2
- 208000024055 brain glioblastoma Diseases 0.000 claims 2
- 201000011609 brain glioblastoma multiforme Diseases 0.000 claims 2
- 201000007983 brain glioma Diseases 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 108091070501 miRNA Proteins 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- -1 monoalkylamino Chemical group 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 2
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 2
- PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 description 1
- PBCZSGKMGDDXIJ-UHFFFAOYSA-N 7beta-hydroxystaurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3C(O)NC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 PBCZSGKMGDDXIJ-UHFFFAOYSA-N 0.000 description 1
- KOZFSFOOLUUIGY-SOLYNIJKSA-N K-252a Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@](C(=O)OC)(O)[C@]4(C)O1 KOZFSFOOLUUIGY-SOLYNIJKSA-N 0.000 description 1
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
- OTPNDVKVEAIXTI-UHFFFAOYSA-N LSM-1274 Chemical compound C12=C3C4=C5C=CC=C[C]5N3C(O3)CCC3N2C2=CC=C[CH]C2=C1C1=C4C(=O)NC1=O OTPNDVKVEAIXTI-UHFFFAOYSA-N 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 229950010895 midostaurin Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20125795 | 2012-07-13 | ||
| FI20125795 | 2012-07-13 | ||
| PCT/FI2013/050745 WO2014009609A1 (en) | 2012-07-13 | 2013-07-11 | Combination therapy iii |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015527316A JP2015527316A (ja) | 2015-09-17 |
| JP2015527316A5 true JP2015527316A5 (enExample) | 2016-09-01 |
| JP6393682B2 JP6393682B2 (ja) | 2018-09-19 |
Family
ID=48917570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521033A Expired - Fee Related JP6393682B2 (ja) | 2012-07-13 | 2013-07-11 | 併用療法ｉｉｉ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10166241B2 (enExample) |
| EP (1) | EP2872631B1 (enExample) |
| JP (1) | JP6393682B2 (enExample) |
| CN (1) | CN104619845A (enExample) |
| CA (1) | CA2878873C (enExample) |
| DK (1) | DK2872631T3 (enExample) |
| ES (1) | ES2627500T3 (enExample) |
| WO (1) | WO2014009609A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106344923B (zh) * | 2016-09-23 | 2019-09-27 | 中国人民解放军第二军医大学第二附属医院 | 组蛋白去乙酰化酶-4抑制剂在制备治疗多发性骨髓瘤疾病药物中的应用 |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6133437A (en) | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
| US7741298B2 (en) * | 1997-06-20 | 2010-06-22 | New York University | Method and compositions for inhibiting tumorigenesis |
| JP2002526450A (ja) | 1998-09-18 | 2002-08-20 | スミスクライン・ビーチャム・コーポレイション | Ｃｈｋ１キナーゼ阻害物質 |
| US6214986B1 (en) | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
| WO2002081628A2 (en) | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| US20030190635A1 (en) | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
| CN1646558B (zh) * | 2002-02-20 | 2010-05-12 | 国立大学法人九州工业大学 | 组蛋白脱乙酰酶抑制剂 |
| WO2004017991A1 (en) | 2002-08-13 | 2004-03-04 | Cell Center Cologne Gmbh | Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin’s lymphomas |
| EP1658304A4 (en) | 2002-09-28 | 2009-01-14 | Massachusetts Inst Technology | THERAPY ANTIGRIPPALE |
| US20040077084A1 (en) | 2002-10-17 | 2004-04-22 | Isis Pharmaceuticals Inc. | Antisense modulation of histone deacetylase 4 expression |
| US20040077083A1 (en) * | 2002-10-17 | 2004-04-22 | Isis Pharmaceuticals Inc. | Antisense modulation of histone deacetylase 4 expression |
| EP1560931B1 (en) | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| CA2523517C (en) | 2003-04-25 | 2013-07-30 | Dana-Farber Cancer Institute, Inc. | Bcl2l12 polypeptide activators and inhibitors |
| US20050043266A1 (en) | 2003-07-25 | 2005-02-24 | Sumedha Jayasena | Short interfering RNA as an antiviral agent for hepatitis C |
| WO2005011598A2 (en) | 2003-07-31 | 2005-02-10 | University Of South Florida | Leukemia treatment method and composition |
| CA2533861A1 (en) | 2003-08-08 | 2005-02-17 | Novartis Ag | Combinations comprising staurosporines |
| MX2007001155A (es) | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
| CA2596405A1 (en) * | 2005-02-07 | 2006-08-10 | Topotarget Uk Limited | Assays for agents with selective cytotoxicty to hdac resistant cell lines |
| US20080021198A1 (en) | 2005-10-12 | 2008-01-24 | Yigong Shi | Modulators of protein phosphatase 2A and PP2A methyl esterase |
| CN101400362B (zh) * | 2006-02-14 | 2016-10-12 | 哈佛大学校长及研究员协会 | 双官能组蛋白去乙酰化酶抑制剂 |
| GB0612542D0 (en) | 2006-06-23 | 2006-08-02 | Novartis Ag | Combinations comprising staurosporines |
| WO2008076954A2 (en) * | 2006-12-15 | 2008-06-26 | Novartis Ag | Heterocycle compounds and methods of use thereof |
| US10611818B2 (en) * | 2007-09-27 | 2020-04-07 | Agilent Technologies, Inc. | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics |
| MX2010003417A (es) * | 2007-10-01 | 2010-09-10 | Lixte Biotechnology Inc | Inhibidores de histona desacetilasa. |
| AU2008338631A1 (en) * | 2007-12-14 | 2009-06-25 | Georgetown University | Histone deacetylase inhibitors |
| US20090274682A1 (en) | 2008-02-05 | 2009-11-05 | The Trustees Of Princeton University | Demethylation and inactivation of protein phosphatase 2a |
| RU2011136641A (ru) | 2009-02-04 | 2013-03-10 | Байпар Сайенсиз, Инк. | Лечение рака легких с применением соединения нитробензамида в комбинации с ингибитором фактора роста |
-
2013
- 2013-07-11 CN CN201380047501.9A patent/CN104619845A/zh active Pending
- 2013-07-11 EP EP13745446.8A patent/EP2872631B1/en not_active Not-in-force
- 2013-07-11 US US14/414,393 patent/US10166241B2/en not_active Expired - Fee Related
- 2013-07-11 CA CA2878873A patent/CA2878873C/en not_active Expired - Fee Related
- 2013-07-11 DK DK13745446.8T patent/DK2872631T3/en active
- 2013-07-11 ES ES13745446.8T patent/ES2627500T3/es active Active
- 2013-07-11 JP JP2015521033A patent/JP6393682B2/ja not_active Expired - Fee Related
- 2013-07-11 WO PCT/FI2013/050745 patent/WO2014009609A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015511638A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| RU2013141559A (ru) | Способ ингибирования клеток опухоли гамартомы | |
| WO2013007708A1 (en) | Medicament for treatment of liver cancer | |
| JP2013510120A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| SI3057959T1 (en) | DNA-PK INHIBITORS | |
| CL2008001898A1 (es) | Compuestos derivados de pirazinona, inhibidores de p38; proceso de preparacion de estos; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende; uso para tratar enferemedades pulmonares obstructivas cronicas y asma. | |
| JP2008535902A5 (enExample) | ||
| JP2009504763A5 (enExample) | ||
| JP2017527532A5 (enExample) | ||
| JP2011006480A5 (enExample) | ||
| JP2011509949A5 (enExample) | ||
| JP2011515397A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| RU2012118974A (ru) | Комбинации ингибитора pi3k и ингибитора мек | |
| JP2013510123A5 (enExample) | ||
| RU2016110096A (ru) | Новое хинолин-замещенное соединение | |
| JP2015531747A5 (enExample) | ||
| JP2008528468A5 (enExample) | ||
| JP2015524472A5 (enExample) | ||
| JP2011507896A5 (enExample) | ||
| JP2013537905A5 (enExample) | ||
| JP2015509102A5 (enExample) |